Oric Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 6, 2024
ORIC$9.23+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | Form | File No. | Exhibit | Filing Date |
| 10.1 · Amendment No.1 to the License and Collaboration Agreement by and between the Registrant and Voronoi Inc., effective March 20, 2024 · Filed herewith | |||||
| 10.2+ · Amended and Restated Outside Director Compensation Policy · Filed herewith | |||||
| 10.3 | Amended and Restated 2022 Inducement Equity Incentive Plan, and form agreements thereunder | 8-K | 001-39269 | 10.1 | 3/29/2024 |
| 10.4 | Stock Purchase Agreement, dated January 20, 2024, by and among the Company and the purchasers therein | 8-K | 001-39269 | 10.1 | 1/22/2024 |
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed herewith | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed herewith | |||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished herewith | |||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished herewith | |||
| 101.INS | INLINE XBRL Instance Document | Furnished herewith | |||
| 101.SCH | INLINE XBRL Taxonomy Extension Schema with Embedded Linkbase Document | Furnished herewith | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Furnished herewith | |||
| + | Indicates management contract or compensatory plan. |
|---|---|
| * | The certifications attached as Exhibits 32.1 and 32.2 that accompany this quarterly report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of ORIC Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.